Topotecan

FDA Approved: * February 2, 2011
Pharm Company: * HOSPIRA
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Topotecan Overview

Topotecan (trade name Hycamtin) is a chemotherapeutic agent that is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. It is used in the form of its hydrochloride salt to treat ovarian cancer, lung cancer and other cancer types. After GlaxoSmithKline received final FDA approval for Hycamtin Capsules on October 15, 2007, topotecan became the first topoisomerase I inhibitor for oral use. Contents 1 Uses 1.1 Experimental uses 1...

Read more Topotecan Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Topotecan

Recent Topotecan Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Topotecan
  • Capsule: 0.25mg, 1mg
  • Injection: 1.5mg, 1mg/ml, 3mg/3ml, 4mg/4ml, 4mg/vial
  • Solution: 1mg/ml (1mg/ml), 3mg/3ml (1mg/ml), 4mg/4ml (1mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Topotecan: (18 results)

Sorted by National Drug Code
  • 0069-0075 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Pfizer Laboratories Div Pfizer Inc.
  • 0409-0302 Topotecan 1 mg/ml Intravenous Injection, Solution, Concentrate by Hospira, Inc.
  • 0703-4714 Topotecan 1 mg/ml Intravenous Injection, Solution, Concentrate by Teva Parenteral Medicines, Inc.
  • 16729-151 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Accord Healthcare Inc.
  • 25021-206 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Sagent Pharmaceuticals
  • 25021-236 Topotecan 1 mg/ml Intravenous Injection, Solution, Concentrate by Sagent Pharmaceuticals
  • 25021-824 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Sagent Pharmaceuticals
  • 45963-615 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Actavis Pharma, Inc.
  • 50742-404 Topotecan 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Ingenus Pharmaceuticals, LLC
  • 55390-370 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Bedford Laboratories
  • 62756-023 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Sun Pharmaceutical Industries Limited
  • 63323-762 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by App Pharmaceuticals, LLC
  • 66435-410 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, for Solution by Three Rivers Pharmaceuticals, LLC.
  • 66758-051 Topotecan 1 mg/ml Intravenous Injection by Sandoz Inc
  • 67457-474 Topotecan Hydrochloride 4 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Mylan Institutional LLC
  • 67457-662 Topotecan 1 mg/ml Intravenous Injection, Solution, Concentrate by Mylan Institutional LLC
  • 69097-262 Topotecan Hydrochloride 4 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution by Cipla USA Inc.
  • 71288-127 Topotecan 4 mg/15ml Intravenous Injection, Powder, Lyophilized, for Solution by Meitheal Pharmaceuticals Inc.

Other drugs which contain Topotecan or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 October 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA